Publications
Detailed Information
Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?
Cited 12 time in
Web of Science
Cited 13 time in Scopus
- Authors
- Issue Date
- 2008-04-30
- Publisher
- Oxford University Press
- Citation
- Jpn J Clin Oncol. 2008;38(6):445-450
- Keywords
- Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Carboplatin/administration & dosage ; Carcinoma/*drug therapy/secondary ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans ; Infusions, Intravenous ; Kaplan-Meiers Estimate ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Ovarian Neoplasms/*drug therapy/pathology ; Paclitaxel/administration & dosage ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
- Abstract
- BACKGROUND: To evaluate the efficacy of three additional cycles of chemotherapy in patients with the International Federation of Gynecology and Obstetrics Stage III or IV, who achieved a complete response after six cycles of intravenous adjuvant paclitaxel/carboplatin after surgery. METHODS: The clinical data of 94 patients with complete response after six cycles of adjuvant paclitaxel/carboplatin after surgery between January 1997 and March 2007 were reviewed retrospectively. Three additional cycles using the same chemotherapy were administered to 57 patients as consolidation chemotherapy (Group 1). Thirty-seven patients without the additional cycles served as controls (Group 2). Disease-free survival (DFS) and overall survival (OS) were evaluated using the Kaplan-Meier method with the log-rank test. The importance of consolidation chemotherapy as a prognostic factor affecting survival was examined using the Cox's proportional hazard analysis. The incidence of chemotherapy-induced hematological toxicities was compared between the two groups using chi-square test. RESULTS: Median DFS and mean OS were not significantly different between the two groups (15 versus 22 months, P = 0.703; 69 versus 73 months, P = 0.891, respectively). Consolidation chemotherapy was not a prognostic factor of survival although optimal debulking surgery and lower value of serum CA-125 levels after six cycles of the chemotherapy were prognostic factors improving DFS (P < 0.01). Grade 3 or 4 leukopenia was more common in patients treated with consolidation chemotherapy than in those not treated (50.9 versus 21.6%, P = 0.004). CONCLUSION: Consolidation chemotherapy using paclitaxel/carboplatin may be inefficient and relatively toxic to advanced-stage epithelial ovarian cancer patients with complete response to six cycles of the same chemotherapy after surgery.
- ISSN
- 1465-3621 (Electronic)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18508785
http://jjco.oxfordjournals.org/cgi/reprint/38/6/445.pdf
https://hdl.handle.net/10371/68043
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.